ORIGINAL ARTICLE

Disease Activity is Associated with Depression and Anxiety in Cushing's Syndrome During COVID-19 Pandemic
COVID-19 Pandemisi Sırasında Cushing’s Sendromunda Depresyon ve Anksiyetenin Hastalık Aktivitesi ile İlişkisi
Received Date : 23 Feb 2021
Accepted Date : 10 Mar 2021
Available Online : 24 Mar 2021
Doi: 10.25179/tjem.2021-82526 - Makale Dili: EN
Turk J Endocrinol Metab. 2021;25:166-173
Bu makale, CC BY-NC-SA altında lisanslanmış açık erişim bir makaledir.
ABSTRACT
Objective: To assess the depression and anxiety and their relationship with disease activity in patients with Cushing's syndrome (CS) in the coronavirus disease-2019 (COVID-19) pandemic. Material and Methods: This cross-sectional study included 54 patients with CS (48 females, 6 males). Beck Depression Inventory-II (BDI-II), State-Trait Anxiety Inventory (STAI)-State, STAI-Trait were used to evaluate scores and severity of depression, the current state of anxiety, and general anxiety, respectively. Patients with active CS (n=10) were recorded as group 1, those who were still receiving glucocorticoid replacement therapy after surgery (n=14) as group 2, and those in remission (n=30) as group 3. The groups were compared in terms of parameters that could affect anxiety and depression scores. Correlation analyses were also performed. Results: BDI-II scores were higher in group 1 than group 3 (p=0.002), and STAI-State scores were higher in group 1 than group 2 (p=0.03) while STAI-Trait scores and the other parameters were similar between the groups. Moderate and severe depression were detected in 60% of group 1, 25% of group 2, and 16% of group 3 patients. High state anxiety was seen in 70% of patients in group 1, 50% of group 2, and 57% of group 3 patients. Positive correlations between BDI-II scores and disease activity (r=0.438, p=0.001) and STAI-State scores and disease activity (r=0.297, p=0.029) were observed. Conclusion: Increased depression and state anxiety during the pandemic in patients with active CS suggests that psychiatric disorders may increase in those with a higher risk of severe COVID-19 disease.
ÖZET
Amaç: Koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)] pandemisinde, Cushing sendromlu (CS) hastalarda depresyon ve anksiyete durumunu ve bunların hastalık aktivitesiyle ilişkisini değerlendirmek. Gereç ve Yöntemler: Bu kesitsel çalışma, 54 (48 kadın, 6 erkek) CS’li hastayı içermektedir. Beck Depresyon Envanteri-II (BDI-II), Durumluk Anksiyete Ölçeği [State-Trait Anxiety Inventory (STAI)]-State, Sürekli Anksiyete Ölçeği State-Trait (STAI) testleri; sırasıyla depresyon ciddiyeti, mevcut anksiyete durumu ve genel anksiyeteyi değerlendirmek için kullanılmıştır. Aktif CS’li hastalar (n=10) grup 1, operasyon sonrası hâlen glukokortikoid replasman tedavisi alanlar (n=14) grup 2 ve remisyonda olanlar (n=30) grup 3 olarak kaydedildi. Gruplar, anksiyete ve depresyon puanlarını etkileyebilecek parametreler açısından karşılaştırıldı. Aynı zamanda korelasyon analizleri de yapıldı. Bulgular: BDI-II skorları grup 1’de grup 3’e göre daha yüksek (p=0,002) ve STAI-State skorları grup 1’de grup 2’ye göre daha yüksek (p=0,03) iken, STAI-Trait skorları ve diğer parametreler gruplar arasında benzer saptandı. Grup 1’deki hastaların %60’ında, grup 2’de %25’inde ve grup 3’te %16’sında orta ve şiddetli depresyon saptandı. Grup 1’de hastaların %70’inde, grup 2’de %50 ve grup 3’te %57’sinde yüksek durumluk anksiyete saptandı. BDI-II skorları ile hastalık aktivitesi (r=0,438, p=0,001) ve STAI-State skorları ile hastalık aktivitesi (r=0,297, p=0,029) arasında pozitif korelasyon saptandı. Sonuç: Aktif CS’li hastalarda pandemi sırasında artan depresyon ve durumluk anksiyetesi, şiddetli COVID-19 hastalık riski yüksek olanlarda psikiyatrik bozuklukların artabileceğini düşündürmektedir.
KAYNAKLAR
  1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720. [Crossref]  [PubMed]  [PMC] 
  2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239-1242. [Crossref]  [PubMed] 
  3. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323:2052-2059. Erratum in: JAMA. 2020;323:2098. [Crossref]  [PubMed]  [PMC] 
  4. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323:1775-1776. Erratum in: JAMA. 2020;323:1619. [Crossref]  [PubMed] 
  5. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31:1003-1008. [Crossref]  [PubMed]  [PMC] 
  6. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2950-2973. [Crossref]  [PubMed]  [PMC] 
  7. Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci. 2020;77:8-12. [Crossref]  [PubMed]  [PMC] 
  8. Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020;83:521-523. [Crossref]  [PubMed]  [PMC] 
  9. Dubey S, Biswas P, Ghosh R, Chatterjee S, Dubey MJ, Chatterjee S, Lahiri D, Lavie CJ. Psychosocial impact of COVID-19. Diabetes Metab Syndr. 2020;14:779-788. [Crossref]  [PubMed]  [PMC] 
  10. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540. [PubMed]  [PMC] 
  11. Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4:611-629. [Crossref]  [PubMed] 
  12. Fareau GG, Vassilopoulou-Sellin R. Hypercortisolemia and infection. Infect Dis Clin North Am. 2007;21:639-657, viii. [Crossref]  [PubMed] 
  13. Pivonello R, Simeoli C, De Martino MC, Cozzolino A, De Leo M, Iacuaniello D, Pivonello C, Negri M, Pellecchia MT, Iasevoli F, Colao A. Neuropsychiatric disorders in Cushing's syndrome. Front Neurosci. 2015;9:129. [Crossref]  [PubMed]  [PMC] 
  14. Starkman MN, Schteingart DE, Schork MA. Depressed mood and other psychiatric manifestations of Cushing's syndrome: relationship to hormone levels. Psychosom Med. 1981;43:3-18. [Crossref]  [PubMed] 
  15. Sonino N, Fava GA, Raffi AR, Boscaro M, Fallo F. Clinical correlates of major depression in Cushing's disease. Psychopathology. 1998;31:302-306. [Crossref]  [PubMed] 
  16. Dorn LD, Burgess ES, Friedman TC, Dubbert B, Gold PW, Chrousos GP. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab. 1997;82:912-919. [Crossref]  [PubMed] 
  17. Ragnarsson O, Johannsson G. Cushing's syndrome: a structured short- and long-term management plan for patients in remission. Eur J Endocrinol. 2013;169:R139-52. [Crossref]  [PubMed] 
  18. Forget H, Lacroix A, Cohen H. Persistent cognitive impairment following surgical treatment of Cushing's syndrome. Psychoneuroendocrinology. 2002;27:367-383. [Crossref]  [PubMed] 
  19. Bäuerle A, Teufel M, Musche V, Weismüller B, Kohler H, Hetkamp M, Dörrie N, Schweda A, Skoda EM. Increased generalized anxiety, depression and distress during the COVID-19 pandemic: a cross-sectional study in Germany. J Public Health (Oxf). 2020;42:672-678. [Crossref]  [PubMed]  [PMC] 
  20. Pappa S, Ntella V, Giannakas T, Giannakoulis VG, Papoutsi E, Katsaounou P. Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: A systematic review and meta-analysis. Brain Behav Immun. 2020;88:901-907. Erratum in: Brain Behav Immun. 2021;92:245. [Crossref]  [PubMed]  [PMC] 
  21. Lebel C, MacKinnon A, Bagshawe M, Tomfohr-Madsen L, Giesbrecht G. Elevated depression and anxiety symptoms among pregnant individuals during the COVID-19 pandemic. J Affect Disord. 2020;277:5-13. Erratum in: J Affect Disord. 2021;279:377-379. [Crossref]  [PubMed]  [PMC] 
  22. Wang Y, Duan Z, Ma Z, Mao Y, Li X, Wilson A, Qin H, Ou J, Peng K, Zhou F, Li C, Liu Z, Chen R. Epidemiology of mental health problems among patients with cancer during COVID-19 pandemic. Transl Psychiatry. 2020;10:263. [Crossref]  [PubMed]  [PMC] 
  23. Alessi J, de Oliveira GB, Franco DW, Brino do Amaral B, Becker AS, Knijnik CP, Kobe GL, de Carvalho TR, Telo GH, Schaan BD, Telo GH. Mental health in the era of COVID-19: prevalence of psychiatric disorders in a cohort of patients with type 1 and type 2 diabetes during the social distancing. Diabetol Metab Syndr. 2020;12:76. [Crossref]  [PubMed]  [PMC] 
  24. Beck AT, Steer RA, Brown GK. BDI-II, Beck Depression Inventory: Manual. (2nd ed.) Boston: Harcourt Brace; 1996. [Crossref] 
  25. Kapci EG, Uslu R, Turkcapar H, Karaoglan A. Beck Depression Inventory II: Evaluation of the psychometric properties and cut-off points in a Turkish adult population. Depress Anxiety. 2008;25:E104-10. [Crossref]  [PubMed] 
  26. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory (Self-Evaluation Questionnaire) Palo Alto, CA, USA; 7 Consultant Psychologists Press; 1970. [Link] 
  27. Knight RG, Waal-Manning HJ, Spears GF. Some norms and reliability data for the State-Trait Anxiety Inventory and the Zung Self-Rating Depression scale. Br J Clin Psychol. 1983;22:245-249. [Crossref]  [PubMed] 
  28. Öner N, Compte AL. Süreksiz Durumluluk/Sürekli Kaygı Envanteri El Kitabı. (2. Baskı). İstanbul; Boğaziçi Üniversitesi Yayınevi; 1998. [Link] 
  29. Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S467-72. [Crossref]  [PubMed]  [PMC] 
  30. Hasenmajer V, Sbardella E, Sciarra F, Minnetti M, Isidori AM, Venneri MA. The immune system in Cushing's Syndrome. Trends Endocrinol Metab. 2020;31:655-669. [Crossref]  [PubMed] 
  31. Kakodkar P, Kaka N, Baig MN. A Comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). Cureus. 2020;12:e7560. [Crossref]  [PubMed]  [PMC] 
  32. Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes. Endocr Rev. 2003;24:523-538. [Crossref]  [PubMed] 
  33. Dorn LD, Burgess ES, Dubbert B, Simpson SE, Friedman T, Kling M, Gold PW, Chrousos GP. Psychopathology in patients with endogenous Cushing's syndrome: 'atypical' or melancholic features. Clin Endocrinol (Oxf). 1995;43:433-442. [Crossref]  [PubMed] 
  34. Haskett RF. Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry. 1985;142:911-916. [Crossref]  [PubMed] 
  35. Kelly WF. Psychiatric aspects of Cushing's syndrome. QJM. 1996;89:543-551. [Crossref]  [PubMed] 
  36. Cohen SI. Cushing's syndrome: A psychiatric study of 29 patients. Br J Psychiatry. 1980;136:120-124. [Crossref]  [PubMed] 
  37. Kelly WF, Kelly MJ, Faragher B. A prospective study of psychiatric and psychological aspects of Cushing's syndrome. Clin Endocrinol (Oxf). 1996;45:715-720. [Crossref]  [PubMed] 
  38. Rasmussen SA, Rosebush PI, Smyth HS, Mazurek MF. Cushing disease presenting as primary psychiatric illness: A case report and literature review. J Psychiatr Pract. 2015;21:449-457. [Crossref]  [PubMed] 
  39. Santos A, Granell E, Gómez-Ansón B, Crespo I, Pires P, Vives-Gilabert Y, Valassi E, Webb SM, Resmini E. Depression and anxiety scores are associated with amygdala volume in cushing's syndrome: preliminary study. Biomed Res Int. 2017;2017:2061935. [Crossref]  [PubMed]  [PMC] 
  40. Sonino N, Fallo F, Fava GA. Psychosomatic aspects of Cushing's syndrome. Rev Endocr Metab Disord. 2010;11:95-104. [Crossref]  [PubMed] 
  41. Loosen PT, Chambliss B, DeBold CR, Shelton R, Orth DN. Psychiatric phenomenology in Cushing's disease. Pharmacopsychiatry. 1992;25:192-198. [Crossref]  [PubMed]